M Grundman
Overview
Explore the profile of M Grundman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
2979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vijverberg E, de Haan W, Scheijbeler E, Hamby M, Catalano S, Scheltens P, et al.
J Prev Alzheimers Dis
. 2024 Nov;
11(6):1809-1817.
PMID: 39559892
Background: CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from...
2.
Lizama B, North H, Pandey K, Williams C, Duong D, Cho E, et al.
Neurobiol Dis
. 2024 Jun;
199():106575.
PMID: 38914170
CT1812 is a novel, brain penetrant small molecule modulator of the sigma-2 receptor (S2R) that is currently in clinical development for the treatment of Alzheimer's disease (AD). Preclinical and early...
3.
Michelson D, Grundman M, Magnuson K, Fisher R, Levenson J, Aisen P, et al.
J Prev Alzheimers Dis
. 2019 Nov;
6(4):228-231.
PMID: 31686093
The engineered fusion protein NPT088 targets amyloid in vitro and in animal models of Alzheimer's disease. Previous studies showed that NPT088 treatment reduced β-amyloid plaque and tau aggregate loads in...
4.
5.
6.
Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, et al.
J Prev Alzheimers Dis
. 2017 Nov;
4(2):116-124.
PMID: 29186281
At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned...
7.
Doraiswamy P, Sperling R, Johnson K, Reiman E, Wong T, Sabbagh M, et al.
Mol Psychiatry
. 2014 Mar;
19(9):1044-51.
PMID: 24614494
This study was designed to evaluate whether subjects with amyloid beta (Aβ) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without Aβ pathology. Sixty-nine...
8.
Lacey L, Niecko T, Leibman C, Liu E, Grundman M
J Nutr Health Aging
. 2013 Oct;
17(9):745-50.
PMID: 24154646
Objective: To compare the associations between dependence and clinical measures of cognition, function and behaviour and total care cost using data from a longitudinal study in Alzheimer's disease (AD). Design:...
9.
Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach J, et al.
AJNR Am J Neuroradiol
. 2013 Apr;
34(10):1958-65.
PMID: 23578674
Background And Purpose: AD is one of the few leading causes of death without a disease-modifying drug; however, hopeful agents are in various phases of development. MR imaging abnormalities, collectively...
10.
Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E
J Nutr Health Aging
. 2013 Jan;
17(1):51-3.
PMID: 23299380
Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies....